GLP-1 basics from a PA: what holds up and what doesn't

What did @josharnoldpa actually say?

A PA on TikTok responded to a viewer switching from semaglutide (Ozempic) to tirzepatide (Mounjaro) because her current medication had "stopped working." His core claims: the transition will not cause increased side effects, weight loss results may actually improve, and the switch is straightforward because she's already been on a GLP-1. He also recommended continuing injections, watching diet, and exercising.

He got a few things right. But a couple of claims are fuzzier than he made them sound, and one important nuance about the mechanism difference between these two drugs went completely unaddressed.

Does the science back this up?

Partially, yes. The claim that tirzepatide may produce better weight loss outcomes than semaglutide has real evidence behind it. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide 15mg produced mean weight loss of around 20.9% body weight in adults with obesity. Head-to-head data is harder to find, but a 2023 retrospective study by Patoulias et al. in the Journal of Cardiovascular Pharmacology found tirzepatide associated with greater weight reduction compared to semaglutide in real-world patients.

The "no increased side effects" claim is trickier. Both drugs share GI side effect profiles because they both activate the GLP-1 receptor. But tirzepatide also activates GIP receptors, which is a different mechanism. Tolerability overlap is plausible, but it is not guaranteed. Some patients do experience a recalibration period. The evidence here is not as clean as the PA suggested.

What did they get wrong (or right)?

Credit where it is due: recommending the switch is reasonable, and the note about diet and exercise is appropriate. GLP-1 medications are not a replacement for lifestyle changes, and that framing is consistent with clinical guidelines from the American Diabetes Association (2024 Standards of Care).

What he got wrong, or at least oversimplified: saying "you will not have any increasing symptoms or side effects" is too confident. Tirzepatide is a dual GIP/GLP-1 agonist. It is not simply a stronger semaglutide. Patients tolerating semaglutide well may still experience nausea, vomiting, or GI distress when starting tirzepatide, particularly as doses escalate. A 2023 review by Frías et al. in Diabetes Care noted that GI adverse events are among the most common reasons for discontinuation across both drug classes.

He also did not address what "stopped working" actually means clinically. Plateau in weight loss after months on a GLP-1 is common and does not always mean the drug has failed. Dose escalation or reassessing adherence factors would be worth exploring before switching entirely.

What should you actually know?

If you are considering switching from semaglutide to tirzepatide, here is what the evidence actually supports. First, tirzepatide has a different receptor profile and the two drugs are not interchangeable in terms of mechanism. Second, switching may come with a new titration period and its own side effect window. Do not assume your GI tolerance from semaglutide transfers automatically.

Third, the concept of a GLP-1 "stopping working" deserves more scrutiny from a clinician than a 60-second TikTok reply. Weight loss plateaus are normal on any medication and can reflect physiological adaptation, not drug failure. A proper evaluation should look at dosing history, adherence, dietary patterns, and any comorbid factors before concluding the drug has failed.

Finally: if you are using a compounded version of either semaglutide or tirzepatide, it is not equivalent to the FDA-approved brand-name drug. Compounded formulations are not evaluated by the FDA for safety, efficacy, or potency in the same way.